Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.
via Wikipedia infobox
via PubMed
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 464197511 | image = Pazopanib.svg | image_class = skin-invert-image | width = 275 | alt =
| pronounce = | tradename = Votrient | Drugs.com = | MedlinePlus = a610013 | DailyMedID = Pazopanib | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = L01 | ATC_suffix = EX03 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).